ReviewFunctional & integrative genomics2026
SOX18 at the crossroads of cancer: integrating signaling pathways to drive malignant transformation and immune evasion.
Review in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cancer persists as a leading global cause of mortality. Within this complex landscape, transcription factors (TFs) are pivotal drivers, orchestrating tumor cell phenotypic plasticity and remodeling the immunosuppressive tumor microenvironment through downstream gene regulation. Beyond its established roles in embryonic development and angiogenesis, the SOX (SRY-related HMG-box) family member SOX18 has now been implicated as a critical oncogenic player. Mounting evidence reveals SOX18 overexpression across diverse malignancies, where it actively drives key malignant hallmarks including tumor initiation, metastatic progression, and immune evasion. This review synthesizes the latest advances elucidating the multifaceted roles of SOX18 in cancer pathogenesis. Our aim is to highlight SOX18’s potential as a novel therapeutic target and guide the development of innovative intervention strategies to optimize clinical cancer management.
Indexed as
Identifiers
41857336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.